12,729 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by VELA Investment Management LLC

VELA Investment Management LLC bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 12,729 shares of the biopharmaceutical company’s stock, valued at approximately $729,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Whittier Trust Co. acquired a new position in shares of Halozyme Therapeutics in the 1st quarter worth approximately $27,000. GAMMA Investing LLC increased its holdings in Halozyme Therapeutics by 96.6% during the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 254 shares in the last quarter. International Assets Investment Management LLC bought a new position in Halozyme Therapeutics during the 2nd quarter worth about $33,000. Skandinaviska Enskilda Banken AB publ bought a new position in Halozyme Therapeutics during the 2nd quarter worth about $49,000. Finally, Fidelis Capital Partners LLC bought a new position in shares of Halozyme Therapeutics in the 1st quarter valued at about $52,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total transaction of $532,600.00. Following the sale, the senior vice president now owns 173,756 shares of the company’s stock, valued at $9,254,244.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total value of $532,600.00. Following the sale, the senior vice president now owns 173,756 shares of the company’s stock, valued at approximately $9,254,244.56. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Matthew L. Posard sold 9,881 shares of the company’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total transaction of $570,133.70. Following the completion of the transaction, the director now owns 69,874 shares in the company, valued at approximately $4,031,729.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 89,881 shares of company stock worth $5,169,834 over the last three months. 2.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

HALO has been the subject of a number of research analyst reports. HC Wainwright lifted their price target on Halozyme Therapeutics from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Friday. The Goldman Sachs Group raised their price objective on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research report on Monday, July 22nd. TD Cowen raised their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. Finally, Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.00.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock traded up $6.58 on Friday, hitting $57.15. 3,404,028 shares of the company traded hands, compared to its average volume of 1,285,522. The company has a current ratio of 7.41, a quick ratio of 6.21 and a debt-to-equity ratio of 5.19. Halozyme Therapeutics, Inc. has a 12-month low of $33.15 and a 12-month high of $65.53. The firm’s 50-day simple moving average is $56.99 and its 200 day simple moving average is $51.94. The company has a market cap of $7.24 billion, a P/E ratio of 22.15, a P/E/G ratio of 0.49 and a beta of 1.27.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. The firm had revenue of $231.40 million for the quarter, compared to analyst estimates of $204.94 million. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.68 EPS. Analysts expect that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.